Loss of the 14-3-3σ tumor suppressor is a critical event in ErbB2-mediated tumor progression.

UNLABELLED 14-3-3σ is a putative tumor suppressor involved in cell-cycle progression and epithelial polarity. We demonstrate that loss of one or both copies of the conditional 14-3-3σ allele results in accelerated mammary and salivary tumorigenesis in mice expressing an activated erbB2 oncogene under the endogenous erbB2 promoter. Significantly, the majority of tumors bearing a single conditional 14-3-3σ allele lose expression of the remaining 14-3-3σ allele, which is associated with epigenetic methylation of the 14-3-3σ locus. In addition to accelerated tumor onset, in a mouse mammary tumor virus-driven ErbB2 tumor model, loss of 14-3-3σ results in enhanced metastatic phenotype that is correlated with loss of cellular junctions. Taken together, these results provide compelling evidence that 14-3-3σ is a potent tumor suppressor involved in ErbB2-driven breast cancer initiation and metastasis. SIGNIFICANCE 14-3-3σ has been identified as a normal mammary epithelial cell marker frequently downregulated during neoplastic development. Consistent with its potential role as a tumor suppressor, we demonstrate that targeted disruption of 14-3-3σ in a number of epithelial tissues can profoundly impact both the initiation and metastatic phases of ErbB2-mediated tumor progression through modulation of a number of distinct signaling networks.

[1]  W. Muller,et al.  A novel role for 14-3-3sigma in regulating epithelial cell polarity. , 2010, Genes & development.

[2]  M. Hung,et al.  14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. , 2009, Cancer cell.

[3]  U. Rapp,et al.  Regulation of RAF Activity by 14-3-3 Proteins , 2009, Journal of Biological Chemistry.

[4]  Z. Xuan,et al.  Deregulation of Scribble Promotes Mammary Tumorigenesis and Reveals a Role for Cell Polarity in Carcinoma , 2008, Cell.

[5]  T. Pawson,et al.  ShcA signalling is essential for tumour progression in mouse models of human breast cancer , 2008, The EMBO journal.

[6]  Stephen T. Brown,et al.  An EGR2/CITED1 Transcription Factor Complex and the 14-3-3σ Tumor Suppressor Are Involved in Regulating ErbB2 Expression in a Transgenic-Mouse Model of Human Breast Cancer , 2007, Molecular and Cellular Biology.

[7]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[8]  Marissa E. Nolan,et al.  Par6–aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control , 2006, Nature Cell Biology.

[9]  D. Lodygin,et al.  Epigenetic silencing of 14-3-3sigma in cancer. , 2006, Seminars in Cancer Biology.

[10]  I. Verma,et al.  Identification of 14-3-3sigma mutation causing cutaneous abnormality in repeated-epilation mutant mouse. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Gray,et al.  Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling. , 2005, Cancer research.

[12]  L. Siracusa,et al.  A mutation in stratifin is responsible for the repeated epilation (Er) phenotype in mice , 2005, Nature Genetics.

[13]  John R Yates,et al.  Targeted Proteomic Analysis of 14-3-3ς, a p53 Effector Commonly Silenced in Cancer*S , 2005, Molecular & Cellular Proteomics.

[14]  D. Lodygin,et al.  The role of epigenetic inactivation of 14-3-3σ in human cancer , 2005, Cell Research.

[15]  H. Yoshida,et al.  Frequent downregulation of 14-3-3 σ protein and hypermethylation of 14-3-3 σ gene in salivary gland adenoid cystic carcinoma , 2004, British Journal of Cancer.

[16]  Hye Kyong Kweon,et al.  Phosphorylation-Dependent Binding of 14-3-3 to the Polarity Protein Par3 Regulates Cell Polarity in Mammalian Epithelia , 2003, Current Biology.

[17]  Satoshi Inoue,et al.  Efp targets 14-3-3σ for proteolysis and promotes breast tumour growth , 2002, Nature.

[18]  T. Ried,et al.  Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu , 2002, Oncogene.

[19]  T. Pandita,et al.  High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  F. Leenders,et al.  Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation , 2000, Oncogene.

[21]  M. Rudnicki,et al.  Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  K. Kinzler,et al.  14-3-3σ is required to prevent mitotic catastrophe after DNA damage , 1999, Nature.

[23]  R. Cardiff,et al.  Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.

[24]  S. Bull,et al.  neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  X. Cullere,et al.  Serine 257 Phosphorylation Regulates Association of Polyomavirus Middle T Antigen with 14-3-3 Proteins , 1998, Journal of Virology.

[26]  K. Kinzler,et al.  14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression , 1997 .

[27]  R. Cardiff,et al.  Activated neu Induces Rapid Tumor Progression (*) , 1996, The Journal of Biological Chemistry.

[28]  R. Palmiter,et al.  Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. , 1995, Cancer research.

[29]  C. Croce,et al.  Detection and cloning of a common region of loss of heterozygosity at chromosome 1p in breast cancer. , 1995, Cancer research.

[30]  E. Valverius,et al.  Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary cells. , 1992, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[31]  A. Villa,et al.  Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice. , 1992, Cancer letters.

[32]  O. Garson,et al.  Rearrangement of chromosome 1p in breast cancer correlates with poor prognostic features. , 1992, British Journal of Cancer.

[33]  G. Stenman,et al.  Expression of the ERBB2 protein in benign and malignant salivary gland tumors , 1991, Genes, chromosomes & cancer.

[34]  N. Kernohan,et al.  Expression of c‐erbB‐2 oncoprotein in salivary gland tumours: An immunohistochemical study , 1991, The Journal of pathology.

[35]  R. Palmiter,et al.  Overexpression of TGFα in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast , 1990, Cell.

[36]  B. Hogan,et al.  Development of mammary hyperplasia and neoplasia in MMTV-TGFα transgenic mice , 1990, Cell.

[37]  N. Lemoine,et al.  Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. , 1990, Oncogene.

[38]  P. Jolicoeur,et al.  Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.

[39]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[40]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[41]  P. Leder,et al.  Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo , 1987, Cell.

[42]  K. Semba,et al.  A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[43]  F. Révillion,et al.  Proteomic analysis reveals that 14-3-3σ is down-regulated in human breast cancer cells , 2001 .

[44]  P. Ravdin.  neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer , 1999 .

[45]  A. Knudson.  Introduction to the genetics of primary renal tumors in children. , 1993, Medical and pediatric oncology.

[46]  B. Hogan,et al.  Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. , 1990, Cell.

[47]  D. Weiner,et al.  Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. , 1989, Oncogene.

[48]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[49]  K. Semba.  A v-erbB-related protooncogene, c-erb-B-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma , 1985 .